Generic medicine

Topotecan: Brands, Price & Uses in Bangladesh

Topotecan is a topoisomerase I inhibitor anticancer (cytotoxic chemotherapy) agent used under the supervision of an oncologist.

Forms:Injection

About Topotecan

Indications of Topotecan

Topotecan is a topoisomerase I inhibitor anticancer (cytotoxic chemotherapy) agent used under the supervision of an oncologist. Its evidence-based indications are:

Established / FDA-approved indications

  • Metastatic ovarian cancer — as a single agent, after disease has progressed on or after initial or subsequent chemotherapy.
  • Small cell lung cancer (SCLC), platinum-sensitive disease — as a single agent, in patients who progressed at least 60 days after completing first-line chemotherapy.
  • Stage IV-B, recurrent, or persistent cervical cancer not amenable to curative treatment with surgery and/or radiation — used in combination with cisplatin (combination therapy is required for this indication; Topotecan is not used alone for cervical cancer).

Off-label / investigational use

Topotecan has been studied off-label in other relapsed/refractory solid tumours and paediatric malignancies (e.g., neuroblastoma, rhabdomyosarcoma, Ewing sarcoma) in clinical trial settings; such use should only occur under specialist oncology protocols, as safety and efficacy for these uses are not formally established.

Dosage & Administration of Topotecan

Dosing of Topotecan is indication-specific and calculated by body surface area (BSA, mg/m²). Topotecan must be administered under the supervision of a qualified oncologist, with a baseline and pre-cycle complete blood count (CBC) confirming adequate bone marrow reserve before each dose.

IndicationRegimen
Ovarian cancer / SCLC (single agent)1.5 mg/m² by IV infusion over 30 minutes, once daily for 5 consecutive days, repeated every 21 days (subsequent cycles only after neutrophils ≥1,500/mm³, platelets ≥100,000/mm³, and haemoglobin at an acceptable level)
Cervical cancer (with cisplatin)Topotecan 0.75 mg/m²/day IV over 30 minutes on Days 1, 2, and 3, plus cisplatin 50 mg/m² IV on Day 1 only, repeated every 21 days

Dose modification

  • Renal impairment: creatinine clearance 20–39 mL/min — reduce dose to 0.75 mg/m²/day (ovarian/SCLC regimen); no adjustment needed for creatinine clearance ≥40 mL/min; not recommended if creatinine clearance is below 20 mL/min due to insufficient data.
  • Hepatic impairment: no dose adjustment is established as necessary based on available pharmacokinetic data.
  • Myelosuppression: subsequent cycles are delayed and/or dose-reduced (commonly by 0.25 mg/m² decrements) if severe neutropenia, febrile neutropenia, or severe thrombocytopenia occurred in the prior cycle. See Precautions and Warnings.

See also Dosage, Administration, and Reconstitution sections below for further detail.

Side Effects of Topotecan

Topotecan commonly causes dose-related bone marrow suppression; the most frequent adverse effects seen in clinical trials include:

Very common

  • Neutropenia (including severe/Grade 3–4 neutropenia in a majority of treated patients), anemia, and thrombocytopenia — see Precautions and Warnings for the boxed warning on myelosuppression.
  • Nausea, vomiting, and diarrhoea.
  • Fatigue, weakness (asthenia), and alopecia (hair loss).
  • Fever, and febrile neutropenia in a substantial minority of patients.

Less common but clinically important

  • Interstitial lung disease (rare, but can be fatal — see Precautions and Warnings).
  • Elevated liver enzymes, mucositis, and hypersensitivity reactions.
  • Extravasation-related local tissue reactions at the injection site.

Patients should report fever, unusual bleeding/bruising, severe fatigue, breathlessness, or signs of infection to their oncology team immediately.

Contraindications of Topotecan

Topotecan is contraindicated in:

  • Patients with a known history of severe hypersensitivity to Topotecan or any component of the formulation.
  • Patients with severe, pre-existing bone marrow suppression at baseline (e.g., baseline neutrophil count below 1,500/mm³ or platelet count below 100,000/mm³) before starting the first treatment cycle.

Topotecan is not an antibiotic; no antimicrobial stewardship restrictions apply.

Frequently Asked Questions about Topotecan

What is Topotecan used for?

Topotecan is a chemotherapy medicine used to treat certain cancers that have progressed after prior chemotherapy, specifically metastatic ovarian cancer, platinum-sensitive small cell lung cancer, and (combined with cisplatin) advanced cervical cancer that cannot be cured with surgery or radiation.

Why do I need frequent blood tests during Topotecan treatment?

Topotecan commonly causes bone marrow suppression, lowering white blood cells (raising infection risk), platelets (raising bleeding risk), and red blood cells (causing anemia). Your oncologist checks your complete blood count before and during every cycle to make sure it is safe to continue, and may delay or reduce the dose if your counts are too low.

Can Topotecan be used during pregnancy?

No. Topotecan can harm a developing fetus and is considered contraindicated in pregnancy. Women of reproductive potential should use effective contraception during treatment and for at least 6 months afterward, and men should use effective contraception for at least 3 months after their last dose. Tell your doctor immediately if you become pregnant during treatment.

What are the most common side effects of Topotecan?

The most common side effects of Topotecan are low blood counts (neutropenia, anemia, thrombocytopenia), nausea, vomiting, diarrhoea, fatigue, hair loss, and fever. Report fever, unusual bleeding or bruising, severe tiredness, or breathing difficulty to your care team right away.

Is Topotecan given as a pill or an injection?

Topotecan is most commonly given as a slow intravenous (IV) infusion over 30 minutes in a chemotherapy clinic or hospital, on specific days of a treatment cycle. An oral capsule form of Topotecan is also available in some markets; if prescribed, capsules must be swallowed whole, not crushed or chewed.

What should I do if I think too much Topotecan was given or taken?

An overdose of Topotecan mainly worsens the risk of severe low blood counts. If overdose is suspected, seek immediate medical attention or contact emergency services/poison control without delay; do not try to manage it at home. Close hospital monitoring and supportive treatment will be needed.

Disclaimer

The information provided is accurate to the best of our knowledge, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy, and the absence of specific information about a drug should not be taken as an endorsement. We are not responsible for any consequences arising from this information, so please consult a healthcare professional for any concerns or questions.

DoctorBlogArticles